Molecular profiles of genomically High Risk ER+ HER2- breast cancer tumors classified as functionally Basal or Luminal B by the BluePrint
PUBLICATION: ASCO 2021 Authors Joyce O’Shaughnessy1, Virginia G. Kaklamani2, Read More
Whole transcriptome analysis comparing HR+ HER2- breast cancer tumors from patients ≤ 50 years and > 50 years
PUBLICATION: ASCO 2021 Authors Cathy Graham1, Douglas K. Marks2, Read More
Gene expression associated with lymphovascular invasion and genomic risk in early-stage breast cancer
PUBLICATION: ASCO 2021 Authors Nina D’Abreo1,2, Abhinav Rohatgi1,2, Douglas Read More
Agendia’s MammaPrint Test is the First to Demonstrate the Ability to Predict Benefit from Extended Endocrine Treatment in NSABP B-42 Trial
MammaPrint was the only test to predict significant 36% and Read More
Analysis of MINDACT Study Confirms MammaPrint Accurately Identifies Extremely Indolent Ultra Low Risk Breast Cancers
Oral presentation at ASCO 2021 highlights long term data with Read More
Agendia Presents Data from Innovative FLEX Study at ASCO 2021 Showing MammaPrint and BluePrint Utility in Wide Variety of Patient Populations
Transcriptomic differences found between Luminal tumors in African American and Read More
ASCO 2021 Podium Presentation on Agendia FLEX Study Shows Clinical & Molecular Differences in Tumors of African American and Caucasian Patients with HR+ Breast Cancer, Underscores Importance of Genomic Insights to Understand Disparities in Outcomes
Transcriptomic differences found between Luminal tumors in African American and Read More
Inivata and Agendia Sign Agreement for Commercialization of RaDaR® MRD Liquid Biopsy Assay in Breast Cancer
Inivata and Agendia Sign Agreement for Commercialization of RaDaR® MRD Liquid Biopsy Assay in Breast Read More
MammaPrint, BluePrint, and Full-genome Data Linked with Clinical Data to Evaluate New Gene EXpression Profiles (FLEX): A real-world dataset and investigator-initiated protocols in ESBC
Publication: St. Gallen Authors: Jennifer A. Crozier, Lisa Blumencranz, Read More
5-year distant metastasis-free survival outcomes on the pre-operative use of MammaPrint and BluePrint for neoadjuvant decisions in the NBREaST II trial
Publication: St. Gallen Authors: E. Göker, M.P. Hendriks, M. van Read More
